Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system.
about
Effects of a high fat meal matrix and protein complexation on the bioaccessibility of blueberry anthocyanins using the TNO gastrointestinal model (TIM-1).Considerations for extrapolating in vivo bioequivalence data across species and routes.MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis.Mesalamine with MMX technology for the treatment of ulcerative colitis.Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis.Once daily, high-dose mesalazine controlled-release tablet for colonic delivery: optimization of formulation variables using Box-Behnken design.Increased bioavailability of celecoxib under fed versus fasted conditions is determined by postprandial bile secretion as demonstrated in a dynamic gastrointestinal model.Dissolution of Commercially Available Mesalamine Formulations at Various pH Levels.An investigation into the utility of a multi-compartmental, dynamic, system of the upper gastrointestinal tract to support formulation development and establish bioequivalence of poorly soluble drugs.Influence of some formulation variables on the optimization of pH-dependent, colon-targeted, sustained-release mesalamine microspheres5-ASA in ulcerative colitis: improving treatment compliance.Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis.MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis.
P2860
Q33811166-A3ED1144-DA20-4E00-8323-0D4F4B07413FQ34194145-F5DF7CC5-29E0-4A4C-AD48-33B32F1663ECQ37123430-F1CFB957-8A27-486C-9E32-8DA53B6D8C99Q37345925-9BAAE9B3-2208-4929-B795-5778C8F40A01Q38042702-9F60769D-F791-4299-982B-63028EEE0786Q39422707-01B14EA3-74B5-4C15-AF0E-AEBF981AAE0FQ40119648-84E9B994-4B6C-4A47-818B-815662747A6AQ41518791-23C8B90C-0368-463B-8B3C-0FF6B2DA8AC2Q41868429-4E2BED75-4825-4D57-9A40-798E540BD2C7Q41896701-3D462985-05CF-4EDD-9B0E-D096EE60FBC9Q42560059-4905E2C1-5DBA-4574-BC79-AF6A19FDE3DCQ43769282-81A34F6E-93FD-4D9F-B6EC-82D6B7F052FBQ55439079-58D10B51-30C8-4031-A90E-FDD44F4B5C01
P2860
Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Release of 5-aminosalicylate f ...... gastrointestinal tract system.
@en
Release of 5-aminosalicylate f ...... gastrointestinal tract system.
@nl
type
label
Release of 5-aminosalicylate f ...... gastrointestinal tract system.
@en
Release of 5-aminosalicylate f ...... gastrointestinal tract system.
@nl
prefLabel
Release of 5-aminosalicylate f ...... gastrointestinal tract system.
@en
Release of 5-aminosalicylate f ...... gastrointestinal tract system.
@nl
P2093
P356
P1433
P1476
Release of 5-aminosalicylate f ...... gastrointestinal tract system.
@en
P2093
Evelijn Zeijdner
Luigi Moro
Roberto Villa
Srini Tenjarla
Vallente Romasanta
P2860
P2888
P304
P356
10.1007/BF02849976
P407
P577
2007-07-01T00:00:00Z